Brainstem auditory pathway of children with acute lymphoid leukemia on chemotherapy with methotrexate

Via auditiva em tronco encefálico de crianças com leucemia linfoide aguda em quimioterapia com metotrexato

Abstract

Objective:

Investigate the auditory pathway in the brainstem of children with acute lymphoblastic leukemia submitted to chemotherapy (by intravenous or intrathecal infusion).

Methods:

Fourteen children aged between 2 and 12 years with diagnosis of acute lymphoid leukemia were evaluated. The following procedures were used: meatoscopy, acoustic immitance measurements, tonal audiometry, vocal audiometry, transient otoacoustic emissions, and auditory brainstem response.

Results:

From the 14 children with normal auditory thresholds, 35.71% showed an alteration in auditory brainstem response, with a predominance of hearing impairment in the lower brainstem. It was found that 80% of the children with alteration had used intrathecal methotrexate less than 30 days and that 40% had the highest cumulative intravenous methotrexate doses.

Conclusion:

Children with acute lymphoblastic leukemia submitted to chemotherapy, present auditory pathway impairment in the brainstem, with a predominance of a low brainstem.

Keywords:
hearing; electrophysiology; precursor cell lymphoblastic leukemia-lymphoma; drug therapy; methotrexate; child

Resumo

Objetivo:

Investigar a via auditiva em tronco encefálico de crianças com leucemia linfoide aguda submetidas à quimioterapia (por infusão intravenosa ou por via intratecal).

Métodos:

Foram avaliadas 14 crianças com idade entre 2 e 12 anos, com diagnóstico de leucemia linfoide aguda. Foram utilizados os seguintes procedimentos: meatoscopia, medidas de imitância acústica, audiometria tonal, audiometria vocal, emissões otoacústicas transientes e potencial evocado auditivo de tronco encefálico.

Resultados:

Das 14 crianças com limiares auditivos normais, 35,71% demonstraram alteração no Potencial Evocado Auditivo de Tronco Encefálico, com predomínio de comprometimento de via auditiva em tronco encefálico baixo. Verificou-se que 80% das crianças com alteração haviam feito uso do metotrexato via intratecal a menos de 30 dias e que 40% tinham as maiores doses acumulativas de metotrexato por via endovenosa.

Conclusão:

Crianças com leucemia linfoide aguda submetidas à quimioterapia apresentam comprometimento na via auditiva em tronco encefálico, com predomínio em tronco encefálico baixo.

Palavras-chave:
audição; eletrofisiologia; leucemia-linfoma linfoblástico de células precursoras; tratamento farmacológico; metotrexato, criança

Several factors can compromise the auditory pathway, including the drugs used during chemotherapy.

Both normal cells and cancer cells are destroyed from chemotherapeutic drugs, causing secondary problems¹ such as ototoxicity and neurotoxicity.

Several chemotherapeutic drugs are used in the treatment of various types of cancer, such as cisplatin, carboplatin, actinomycin, bleomycin, nitrogen mustards (mustine), misonidazole, vincristine, vinblastine², among others.

Acute lymphoblastic leukemia (ALL) is the most common type of cancer found in young children, and may occur in adults³. In a study that aimed to estimate the prevalence of hearing loss in children and adolescents with cancer, 30.8% of the 94 patients treated in 2003 and 2004 in a referral hospital in São Paulo had ALL⁴.

The GBTLI-LLA99 (Grupo Brasileiro de Tratamento da Leucemia na Infância [Brazilian Group for Leukemia Treatment in Childhood ALL-99 Brazilian]⁵) and BFM95 (developed by the German group Berlin-Frankfurt-Munich)⁶ protocols are used in the treatment of individuals with ALL, and both include the chemotherapeutic drug methotrexate (MTX)⁷.

Although several drugs are used in these protocols, MTX is most commonly reported to cause neurotoxicity after its use^8,9.

MTX is used in the treatment of malignant tumors, both solid and hematological, and can be used in high doses of 3 to 8 g/m² or even higher if necessary. MTX can also be used in low doses (10 to 15 mg) intrathecally for prophylaxis or treatment of leptomeningeal infiltration. Its main indications are ALL and non-Hodgkin's lymphomas, including brain lymphomas and sarcomas (adult and childhood)¹⁰. The neurotoxicity occasioned by MTX^11,12,13 may occur in an acute, subacute, or late form¹⁴ and can be observed after intrathecal or intravenous administration^9,11.

The mechanism that MTX causes neurotoxicity is not fully understood, and more than one mechanism may be involved; however, MTX has been observed to have direct toxicity in brain tissue⁹. The location and degree of toxicity are difficult to determine, and there is no clear correlation between the results of auxiliary tests (MRI, radionuclide brain scan, electroencephalography, neuropsychological tests) and the clinical manifestations⁹.

Because MTX can impair both central and peripheral nervous system, its potential neurotoxicity in the central auditory nervous system (CANS) must be considered. Impairment of this region can impede the understanding of speech and, consequently, the development of speech and language in children, possibly hindering the social interaction of individuals.

To evaluate the CANS, auditory evoked potentials (AEPs) are used to assess neuroelectric activity in the auditory pathway from the auditory nerve to the auditory cortex.

Brainstem auditory evoked potential (BAEP) measurement is an objective test that captures the electrical responses to acoustic stimulation generated in the brainstem. This potential consists of seven waves with well-defined generators^15,16.

BAEPs have been used to investigate ototoxicity in cancer patients undergoing chemotherapy^17,18,19, but the investigation of neurotoxicity with this test has rarely been explored.

In a study using BAEPs to assess neurotoxicity in children and adolescents after chemotherapy with cisplatin, an increase was observed in interpeak I-III value that was associated with normal distortion product otoacoustic emissions (DPOE), suggesting neurotoxicity in the auditory pathway in the brainstem. The authors reported the need for further studies to examine neurotoxicity²⁰.

Therefore, the objective of this study was to investigate the auditory pathway in the brainstem of children with ALL undergoing chemotherapy (intravenously or intrathecally).

METHODS

The present study was approved by the Ethics Committee of the institution under number 53924116.0.0000.0068/2016, and data collection was performed only after the parents or guardians signed an informed consent form and the children signed an assent form.

This is a clinical and cross-sectional study that evaluated 14 children (8 females; 6 males) aged 2 to 12 years (mean age, 8 years 4 months) who were diagnosed with ALL, had no infiltration into the central nervous system as confirmed by examination of the cerebrospinal fluid, and were undergoing chemotherapy. The volunteers were referred by a public reference hospital in the city of São Paulo, where they were undergoing chemotherapy and outpatient follow-up (1 individual in remission - patient 7).

The audiological and electrophysiological evaluation of hearing was performed in a teaching health center, which required patients to travel, justifying why the sample size was small.

It is noteworthy that in some cases the first assessment was revalued, since the population had complications of chemotherapy, and data collection was performed in two sessions of up to 1h30min when necessary.

The doses of MTX were collected using medical records, and the total dose administered intravenously and/or intrathecally until the date of BAEP measurement was obtained. Dosages, frequency, and duration of drug infusion were established according to the risk group in which the patient was entered.

A Heine^® Mini2000™ Otoscope was used to examine the ear canal.

The children were subjected to acoustic immittance evaluations (tympanometry and acoustic reflex measurements) to assess possible middle ear impairment (GN Otometrics tympanometer, model Otoflex100). Pure-tone audiometry at frequencies of 500, 1000, 2000, 4000 Hz (if possible 6000 and 8000 Hz) were used to determine auditory thresholds, and speech audiometry (speech recognition threshold - SRT - and speech recognition percentage index - SRPI, the latter performed in older children) (Grason Stadler audiometer, model GSI-61, ER-3A earphones, sound booth meeting the ANSI S3.1-1991 standard for the amount of ambient noise).

When obtaining auditory thresholds, the ages of the children were considered, and conditioned play audiometry or pure-tone audiometry using earphones were performed.

To obtain the BAEP measurements, the skin was initially cleaned with an abrasive paste, and the electrodes were fixed to the skin of the individual using an electrolyte paste and adhesive tape (micropore), according to the International Electrode System (IES) 10‒20 standard²¹. The impedance values of the electrodes were checked and were below 5kohms.

BAEPs were measured using a click stimulus with rarefied polarity, monoaurally presented at 80dBnHL, at a rate of 27.7 stimuli per second, totalizing 2000 stimuli (Universal Smart Box Jr^TM Smart EP, Intelligent Hearing System-ER-3A earphone for BAEP and ER-10D earphone for otoacoustic emissions-OAEs). In cases where it was not possible to perform conventional pure-tone audiometry or transient otoacoustic emissions (TOAEs), the electrophysiological threshold was obtained using the BAEP, with a normal electrophysiological threshold considered to be up to 20 dBnHL²².

To obtain this potential, it was necessary for the child to remain seated or laying in a recliner in a comfortable position in a sound and electrically treated room.

After collection, for the acoustic immittance measures, normal results were considered to include the presence of a type A tympanogram pattern²³ and ipsilateral acoustic reflexes present at frequencies of 500, 1000, and 2000 Hz between 80 and 95 dBHL²⁴.

Because the higher frequencies of pure-tone audiometry are important in the evaluation of individuals undergoing chemotherapy, the result was classified as normal when auditory thresholds less than or equal to 15 dBHL were observed at frequencies of 500, 1000, 2000, and 4000 Hz (children up to 6 years of age) and when auditory thresholds less than or equal to 20 dBHL were observed at frequencies of 250, 500, 1000, 2000, 4000, 6000, and 8000 Hz (children 7 years old or older).

The speech audiometry result was considered compatible when the SRT showed a response equal to or up to 10 dB above the mean auditory thresholds obtained in pure-tone audiometry for the frequencies of 500, 1000, and 2000 Hz²⁵ and when the SRPI showed a percentage of accuracy between 90 and 100% at an intensity of 30 dB above the SRT²⁶.

Regarding the BAEP, the results were classified as normal and altered for each individual according to whether the absolute latency values of waves I, III, and V, and the interpeak values of I-III, III-V, and I-V were within two standard deviations, as proposed by the literature²⁷.

Subsequently, the types of alterations found in each individual were described: alteration in the lower brainstem auditory pathway (increase of latency values of waves III and V and/or the interpeak values of I-III and I-V); alteration in the upper brainstem auditory pathway (increase of latency values of wave V and/or interpeak values of III-V and/or I-V); when the two alterations occurred concomitantly in the same individual, the type of alteration was classified as both.

Results that did not meet the criteria described above were considered altered. For results to be classified as normal, it was necessary for both ears to present results within the normal range. Results for which at least one ear was compromised were classified as altered.

RESULTS

Regarding the results of the behavioral tests, two children (1 and 6) did not have a conditioned response to the conventional pure-tone audiometry; therefore, the TOAEs were measured. One of the children (subject 1) did not present a response in the TOAE test due to the intense internal noise, while the other (subject 6) had responses at frequencies of 1000, 1500, and 2000 Hz. Both children had electrophysiological thresholds of 20dBnHL bilaterally in the BAEP measurement.

The other children showed normal results on the behavioral tests.

The BAEP results showed that of the 14 children evaluated, 35.71% (1, 2, 4, 8, 11) had some type of alteration, and the predominant type was auditory impairment in the lower brainstem (80%) (Tables 1, 2 and 3).

Table 1.
Characterization of the sample as the use of methotrexate, BAEP result, cerebrospinal fluid collection, and the child's age.

Individuals	age	intravenous MTX cumulative dosage	dosage of the last administration of MTX	days of last administration	intrathecal MTX cumulative dosage	dosage of the last administration of MTX	days of last administration	normal	abnormal	type of alteration	time between cerebrospinal fluid collection and ABR (days)	Result Liquor (neoplastic cells)
1	3a6m	7.600 mg	3.800 mg	54	72 mg	12 mg	22		x	low brainstem	7	negative
2	4a3m	1.447 mg	740 mg	6	48 mg	12 mg	1		x	low brainstem	11	negative
3	4a4m	2.700 mg	1.400 mg	38	36 mg	12 mg	38	X			37	negative
4	4a4m	1.600 mg	200 mg	67	36 mg	12 mg	113		x	low brainstem	103	negative
5	5a2m	710 mg	150 mg	31	48 mg	15 mg	54	X			19	negative
6	3a3m	2.229 mg	1.100 mg	65	64 mg	12 mg	11	X			3	negative
7	6a8m	4.390 mg	330 mg	102	60 mg	12 mg	126	X			193	negative
8	10a8m	8.000 mg	5.000 mg	43	99 mg	12 mg	13		x	low brainstem	8	negative
9	12a6m	5.000 mg	5.000 mg	6	30 mg	15 mg	21	X			1	negative
10	11a	2.250 mg	250 mg	15	24 mg	12 mg	155	X			27	negative
11	10a5m	1.160 mg	920 mg	36	45 mg	15 mg	7		x	high brainstem	7	negative
12	9a7m	2.300 mg	200 mg	9	84 mg	12 mg	9	X			9	negative
13	11a6m	4.550 mg	25 mg	2	24 mg	12 mg	2	X			19	negative
14	12a8m	2.690 mg	30 mg	79	15 mg	15 mg	109	X			18	negative

• MTX: methotrexate; BAEP: brainstem auditory evoked potential.

Table 2.
Distribution of the occurrence of normal and abnormal results and types of alterations on the BAEP observed in children undergoing chemotherapy with methotrexate.

BAEP	n		%
Normal	9		64.29
Abnormal	5		35.71
Type of alteration	Low brainstem		High brainstem		Both
	n	%	n	%	n	%
BAEP	4	80	1	20	0	0

• BAEP: brainstem auditory evoked potential.

Table 3.
BAEP latency values obtained in the sample.

		Latency (ms)						Interpeak (ms)
		I		III		V		I-III		III-V		I-V
Individuals	age	Right	Left	Right	Left	Right	Left	Right	Left	Right	Left	Right	Left
1	3a6m	1.75	1.45	4.20	4.15	5.90	5.90	2.45	2.70	1.70	1.75	4.15	4.45
2	4a3m	1.70	1.65	3.95	4.10	5.70	5.85	2.25	2.45	1.75	1.75	4.00	4.20
3	4a4m	1.60	1.45	3.80	3.80	5.65	5.55	2.20	2.35	1.85	1.75	4.05	4.10
4	4a4m	1.65	1.55	4.05	4.00	5.85	5.70	2.40	2.45	1.80	1.70	4.20	4.15
5	5a2m	1.60	1.50	3.80	3.80	5.75	5.65	2.20	2.30	1.95	1.85	4.15	4.15
6	3a3m	1.60	1.55	3.75	3.80	5.60	5.65	2.15	2.25	1.85	1.85	4.00	4.10
7	6a8m	1.85	1.70	3.70	3.85	5.70	5.75	1.85	2.15	2.00	1.90	3.85	4.05
8	10a8m	1.25	1.25	3.95	3.85	5.70	5.80	2.70	2.60	1.75	1.95	4.45	4.55
9	12a6m	1.55	1.55	3.85	3.75	5.70	5.65	2.30	2.20	1.85	1.90	4.15	4.10
10	11a	1.65	1.45	3.75	3.75	5.80	5.50	2.10	2.30	2.05	1.75	4.15	4.05
11	10a5m	1.75	1.75	3.90	3.90	6.00	6.00	2.15	2.15	2.10	2.10	4.25	4.25
12	9a7m	1.75	1.65	3.75	3.70	5.60	5.55	2.00	2.05	1.85	1.85	3.85	3.90
13	11a6m	1.75	1.55	3.65	3.70	5.50	5.50	1.95	2.10	1.80	1.85	3.75	3.95
14	12a8m	1.75	1.75	3.85	3.85	5.70	5.75	2.10	2.10	1.85	1.90	3.95	4.00

• BAEP: brainstem auditory evoked potential.

We also observed that 60% of children (1, 2, 4) who presented altered BAEPs were younger than 5 years old and that 80% of the children (1, 2, 8, 11) with alterations had received MTX intrathecally less than 30 days before (Table 1).

The 40% of children (1 and 8) who had abnormal BAEP results had the highest cumulative doses of MTX administered intravenously (8.000 mg, subject 1; 7.600 mg, subject 2) and intrathecally (72 mg, subject 1; 99 mg, subject 2) (Table 1).

DISCUSSION

Although data from the literature⁴ show that ALL occurs more frequently in males, in the present study, our sample included mostly females. This may have occurred because the sample number was small.

Conductive impairment was only observed in children younger than 5 years (3 years 7 months), while upper airway impairment was present in both younger and older children. This hindered the measurement of OAEs; therefore, this procedure was performed only in children who did not undergo pure-tone audiometry. These findings are consistent with reports in the literature of individuals undergoing chemotherapy who have both complaints of otitis and upper airway infection⁴.

Chemotherapeutic drugs do not differentiate normal cells from cancer cells; therefore, several types of normal cells are destroyed, causing secondary problems¹, such as ototoxicity⁴. The results of the behavioral tests obtained in the present study showed that the peripheral hearing of children at the frequencies conventionally evaluated was not impaired by chemotherapy because all children had thresholds within the normal range for their age.

However, analysis of the TOAEs for subject 6 (Table 1) showed responses at frequencies of 1000, 1500, and 2000 Hz and no response at frequencies of 3000 and 4000 Hz (higher frequencies) bilaterally. Due to the absence of response to the 3000 and 4000 Hz frequencies, the electrophysiological threshold was obtained using the BAEP, which was 20 dBnHL bilaterally. The medical records showed that this individual had been undergoing chemotherapy for several months, and one of the drugs used was vincristine at a dose of 4.400 mg, which, according to the literature, is considered an ototoxic drug²⁸. These findings suggest that alterations occur in the cochlea and are first detected by the TOAE responses and later by the auditory thresholds obtained in pure-tone audiometry, which would explain the electrophysiological threshold of 20 dBHL bilaterally. In a study involving auditory monitoring in patients undergoing chemotherapy, the TOAE results showed that a response to frequencies of 1000 and 2000 Hz was observed until the end of treatment, while a progressive increase in the absence of responses to frequencies of 3000 and 4000 Hz was observed during treatment²⁹.

In the present study, we found that 5 (35.71%) of the individuals who underwent audiological and electrophysiological assessment of hearing (Tables 1 and 2) showed impairment in the auditory pathway in its most central portion, demonstrating the importance of peripheral and central auditory assessment in this population.

According to the BAEP results, the five individuals mentioned above had some type of alteration, and the predominant type was auditory impairment in the lower brainstem (Tables 1 and 2). These findings suggest possible impairment by MTX, as the literature emphasizes that this drug can cause adverse effects, such as neurotoxicity^11,12,13. In addition, studies have reported that neurotoxicity can occur in an acute, subacute, or chronic form¹⁴ and can be observed after intrathecal or intravenous administration of MTX^9,11. In the present study, it was also observed that the majority of children with alterations had used MTX intrathecally less than 30 days prior.

Other authors have further reported that acute and subacute forms of neurotoxicity may occur during ALL treatment, generally manifesting as neurological signs. In some cases, neurotoxicity is transient and benign, and in other cases, it can be severe and debilitating, leading to permanent neurological deficits⁸.

Because BAEP measurement was not performed prior to MTX administration, and follow-up was not performed, it was not possible to determine when auditory nerve impairment and/or brainstem impairment occurred or the duration of such impairment. According to the literature, the mechanism by which MTX causes neurotoxicity is not fully understood, and more than one mechanism may be involved, but MTX has been shown to have an immediate effect on nerve tissue⁹. The findings of our study suggest that this effect occurred because children exhibited impairment of the auditory nerve/brainstem at 1, 7, and 13 days after administration of MTX.

It was not possible to establish the minimum (or exact) amount of drug likely to impair the lower brainstem region using the results of this study. However, we found that 40% of children who had abnormal BAEP results received the highest cumulative doses of MTX intravenously (8.000 mg, subject 1; 7.600 mg, subject 2) and intrathecally (72 mg, subject 1; 99 mg, subject 2) (Table 1), which are doses considered to be high according to the literature¹⁰.

In addition, the location and degree of toxicity that MTX causes in the central nervous system are difficult to establish⁹, but in the present study most of the impairment occurred in the lower brainstem. The only study found in the literature that used BAEPs to evaluate the central auditory pathway of individuals undergoing chemotherapy showed that these individuals exhibited an increase in the interpeak I-III value²⁰. This result is suggestive of impairment in the lower brainstem auditory pathway.

Studies of BAEP measurement in individuals receiving MTX were not found in the literature; however, in a study that assessed motor evoked potentials, delayed conduction of the stimulus in the peripheral motor nerve as well as impairment of the central nervous system were observed after intrathecal MTX administration³⁰.

It is known that, ABR waves I, III, and V are the largest and most frequently observed waves when compared to waves II and IV that may not be present even in normal individuals. Thus, the present study opted for the analysis of waves I, III, and V and their interpeaks I-III, III-V, and I-V. Normal wave I latency values were observed in all evaluated individuals, and the same was not observed for waves III and V and / or interpeaks I-III, I-V, III-V.

As most children in the present study exhibited alterations in the lower brainstem, it can be inferred that a deficit in nerve conduction of the acoustic stimulus was present in the region proximal to the brainstem of the auditory nerve (wave II) (although the values were not obtained), which is part of the final structure of the peripheral auditory system³¹, that interfered with the latency value of wave III, or there may have been a deficit in the cochlear nucleus region (wave III) located in the brainstem - the first structure of the central auditory nervous system³¹.

In the present study, another important finding was the observation that children younger than five years old were the most susceptible to chemotherapy because most had some type of impairment in the auditory pathway. These findings corroborate a previous study that showed that children and elderly people undergoing chemotherapy are most susceptible to auditory alterations³².

Although MTX is considered neurotoxic, it is important to highlight that there is interindividual variability, which may be due to genetic susceptibility, having as participants the following genes involved: megaline, glutathione S-transferase, cross-complementation group’s excision repair 1 and 2, acylphosphatase 2, and mutations in mitochondrial genes³³. Such variability would explain lower dose individuals in the present study with impairments after drug use (individual 4 intrathecal) and individual with higher dose without alteration (individual 12 intrathecal).

Considering that all individuals in the present study underwent cerebrospinal fluid examination with negative results during the investigation of neoplastic cells (suggesting absence of infiltration into the central nervous system) and that, among the drugs used in the treatment of ALL, MTX is most often referred to by authors as being the main drug related to neurotoxicity, we can infer that the findings of brainstem auditory pathway impairment in the present study might have been caused by the administration of MTX in this population.

Because the auditory nerve is responsible for the tonotopic organization of frequencies (low and high)³¹ (wave II of the BAEP) and the cochlear nucleus is responsible for listening in noisy conditions³⁴ (wave III of the BAEP), impairment in one of these regions, even if temporary, especially in young children, can compromise the development of speech and language and impair their social interaction (family, school).

Although this population is difficult to assess due to the complications of chemotherapy, behavioral assessment of auditory processing would be indicated in individuals with alterations in BAEP, as well as in those with complaints and normal hearing thresholds, aiming at a better direction in the therapeutic treatment and stimulation of impaired auditory skills.

The present study demonstrated that BAEP measurement is a useful tool in the evaluation of individuals undergoing chemotherapy, which demonstrated the importance of peripheral and central auditory evaluation in this population, in addition to audiological monitoring during chemotherapy. Thus, therapeutic strategies can be implemented early to decrease future impairments in this population who are undergoing acquisition and development of speech and language.

Further prospective studies with a larger number of individuals and with BAEP measurements conducted prior to chemotherapy should be performed to better define the auditory impairment of these patients.

In conclusion, children with ALL undergoing chemotherapy exhibit impairment of the brainstem auditory pathway, and the main impairment was located in the auditory pathway in the lower brainstem.

References

• ¹
  Alcoser PW, Rodgers C. Treatment strategies in childhood cancer. J Pediatr Nurs. 2003 Apr;18(2):103-12. https://doi.org/10.1053/jpdn.2003.10
  » https://doi.org/10.1053/jpdn.2003.10
• ²
  Federación Federación de Asociaciones de Implantados Cocleares de España (AICE). Medicamentos Ototóxicos. 2009;22:32. Available from: http://implantecoclear.org/index.php?option=com_content&view=article&id=188:medicamentos-ototoxicos&catid=114:ototoxicos
  » http://implantecoclear.org/index.php?option=com_content&view=article&id=188:medicamentos-ototoxicos&catid=114:ototoxicos
• ³
  Brasil. Ministério da Saúde. Instituto Nacional do Câncer José Alencar Gomes da Silva (INCA). Estimativa 2018: Incidência de Câncer no Brasil. Rio de Janeiro (RJ): INCA; 2018. Available from: http://www1.inca.gov.br/inca/Arquivos/estimativa-2018.pdf
  » http://www1.inca.gov.br/inca/Arquivos/estimativa-2018.pdf
• ⁴
  Silva AM, Latorre MRDO, Cristofani LM, Odone Filho V. A prevalência de perdas auditivas em crianças e adolescentes com câncer. Rev Bras Otorrinolaringol. 2007;73(5):608-614. http://doi.org/10.1590/S0034-72992007000500005
  » http://doi.org/10.1590/S0034-72992007000500005
• ⁵
  Brasil. Ministério da Saúde. Instituto Nacional do Câncer José Alencar Gomesda Silva (INCA Condutas do INCA). Leucemias Agudas na Infância e na Adolescência. Rev Bras Cancerol. 2001;47(3):245-57.
• ⁶
  Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008 May;111(9):4477-89. https://doi.org/10.1182/blood-2007-09-112920
  » https://doi.org/10.1182/blood-2007-09-112920
• ⁷
  Cazé MA, Bueno D, Santos MEF. Estudo referencial de um protocolo quimioterápico para leucemia linfocítica aguda infantil. Rev HCPA. 2010 Apr;30(1):5-12.
• ⁸
  Shuper A, Stark B, Kornreich L, Cohen IJ, Aviner S, Steinmetz A, et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol. 2000 Sep;15(9):573-80. https://doi.org/10.1177/088307380001500902
  » https://doi.org/10.1177/088307380001500902
• ⁹
  Shuper A, Stark B, Kornreich L, Cohen IJ, Avrahami G, Yaniv I. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. IMAJ. 2002 Dec;4(11):1050-3.
• ¹⁰
  Reutenauer S, Chauveau D, Récher C. Surdosage au méthotrexate: complications, prise en charge et prévention High-dose methotrexate: Toxicity, management and prevention. Réanimation. 2009 Oct;18(7):654-8. https://doi.org/10.1016/j.reaurg.2009.06.018
  » https://doi.org/10.1016/j.reaurg.2009.06.018
• ¹¹
  Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-Induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949-59. https://doi.org/10.1200/JCO.2013.53.0808
  » https://doi.org/10.1200/JCO.2013.53.0808
• ¹²
  Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr;109(8):3214-8. https://doi.org/10.1182/blood-2006-08-043646
  » https://doi.org/10.1182/blood-2006-08-043646
• ¹³
  Guzmán T, Rubio S, Poyatos-Ruiz LL, Navarro G. High-doses of methotrexate in osteosarcoma. Does it adjust to a real body surface area? Rev OFIL. 2008;27(1):88-90.
• ¹⁴
  Gaies E, Jebabli N, Trabelsi S, Salouage I, Charfi R, Lakhal M, et al. Methotrexate Side Effects: Review Article. J Drug Metab Toxicol. 2012;3(4):1-5. https://doi.org//10.4172/2157-7609.1000125
  » https://doi.org//10.4172/2157-7609.1000125
• ¹⁵
  Durrant JD, Ferraro JA. Potenciais Evocados Auditivos de curta latência: eletrococleografia e audiometria de tronco encefálico. In: Musiek FE, Rintelmann WF. Perspectivas atuais em avaliação auditiva. São Paulo: Manole; 2001.193-238.
• ¹⁶
  Møller AR, Janetta P, Bennet M, Møller MB. Intracranially recorded responses from the human auditory nerve: new insights into the origin of brain stem evoked potentials (BSEPs). Electroencephalogr Clin Neurophysiol. 1981 Jul;52(1):18-27. https://doi.org/10.1016/0013-4694(81)90184-x
  » https://doi.org/10.1016/0013-4694(81)90184-x
• ¹⁷
  Coupland SG, Ponton CW, Eggermont JJ, Bowen TJ, Grant RM. Assessment of cisplatin-induced ototoxicity using derived-band ABRs. Int J Pediatr Otorhinolaryngol. 1991 Oct;22(3):237-48. https://doi.org/10.1016/0165-5876(91)90078-p
  » https://doi.org/10.1016/0165-5876(91)90078-p
• ¹⁸
  Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D. ABR Obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring. J Am Acad Audiol. 2013 Oct;24(9):769-81. https://doi.org/10.3766/jaaa.24.9.2
  » https://doi.org/10.3766/jaaa.24.9.2
• ¹⁹
  De Lauretis A, De Capua B, Barbieri MT, Bellussi L, Passàli D. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand Audiol. 1999;28(3):139-43.
• ²⁰
  Viana LM, Sampaio ALL, Maia NA, Junqueira RMP, Venosa AR, Oliveira CACP. Auditory Brainstem Responses (ABR) changes in children treated with high doses cisplatin. Int Tinnitus J. 2012;17(2):158-62. https://doi.org/10.5935/0946-5448.20120028
  » https://doi.org/10.5935/0946-5448.20120028
• ²¹
  Klem GH, Lüders HO, Jasper HA, Elger C. The ten-twenty system of the International Federation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1958;52:3-6.
• ²²
  Sousa LCA de, Piza MR de T, Alvarenga KF, Cóser PL. Eletrofisiologia da Audição e Emissões Otoacústicas. Princípios e Aplicações Clínicas. Riberão Preto: Book Toy, 2016. p. 49-87.
• ²³
  Jerger J. Clinical experience with impedance audiometry. Arch Otolaryngol. 1970 Oct;92(4):311-24. https://doi.org/10.1001/archotol.1970.04310040005002
  » https://doi.org/10.1001/archotol.1970.04310040005002
• ²⁴
  Carvallo RMM, Carvalho M, Ishida IM. Auditory profile in individuals with and without CAPD. In: 12^th Annual Convention Exposition of the American Academy of Audiology. Chicago, USA; 2000. p.195.
• ²⁵
  Santos TMM, Russo ICP. Logoaudiometria. In: Santos TMM, Russo ICP. A prática da audiologia clínica. 4. ed. São Paulo: Cortez; 1986. p. 81-98.
• ²⁶
  Jerger J, Speaks C, Trammell J. A new approach to speech audiometry. J Speech Hear Disord. 1968 Nov;33(4):318-28.
• ²⁷
  Gonçalves IC, Andrade CRF, Matas CG. Auditory Processing of Speech and Non-Speech Stimuli in Children who Stutter: Electrophysiological Evidences. Brain Disord Ther. 2015;4(5):1-5. https://doi.org/10.4172/2168-975X.1000199
  » https://doi.org/10.4172/2168-975X.1000199
• ²⁸
  Costa JC, Buss CH. Análise de prontuários de pacientes oncológicos quanto ao monitoramento auditivo. Rev CEFAC. 2009 Apr/Jun;11(2):323-30. http://dx.doi.org/10.1590/S1516-18462009000200018
  » http://dx.doi.org/10.1590/S1516-18462009000200018
• ²⁹
  Garcia AP, Iório MCM, Petrilli AS. Monitoramento da audição de pacientes expostos à cisplatina. Rev Bras Otorrinolaringol. 2003 Mar/Apr;69(2):215-21. http://doi.org/10.1590/S0034-72992003000200011
  » http://doi.org/10.1590/S0034-72992003000200011
• ³⁰
  Harila‐Saari AH, Huuskonen UE, Tolonen U, Vainionpää LK, Lanning BM. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: A study with motor evoked potentials. Med Pediatr Oncol. 2001 Mar;36(3):345-51. https://doi.org/10.1002/mpo.1084
  » https://doi.org/10.1002/mpo.1084
• ³¹
  Musiek FE, Baran JA. Overview of the anatomy and Physiology of the Auditory System. San Diego CA.: Plural Publishing INC; 2016. (The Auditory System - Anatomy, Physiology and Clinical Correlates. 1- 37).
• ³²
  Schacht J, Talaska AE, Rybak LP. Cisplatin and Aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken). 2012 Nov;295(11):1837-50. https://doi.org/10.1002/ar.22578
  » https://doi.org/10.1002/ar.22578
• ³³
  Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston Ototoxicity Scale. J Clin Oncol. 2012 Jul 1;30(19):2408-17. https://doi.org/10.1200/JCO.2011.39.1110
  » https://doi.org/10.1200/JCO.2011.39.1110
• ³⁴
  Masterton RB, Granger EM, Glendenning KK. Role ofacoustic stria in hearing: Mechanism for enhancement of sound detection in cats. Hear Res. 1994;73(2):209-22.

• Support: Conselho Nacional de Desenvolvimento Científico e Tecnológico como Bolsa de Pós-Doutorado Processo No 166207/2015-2.

• ERRATUM

  https://doi.org/10.1590/0004-282X20190139erratum
  In the manuscript “Brainstem auditory pathway of children with acute lymphoid leukemia on chemotherapy with methotrexate”, DOI: 10.1590/0004-282X20190139, published in the Arq. Neuro-Psiquiatr. 2020;78(2):63-69. Epub Jan 31, 2020, on page 63.
  Where it reads:
  Carla Gentile MATAS https://orcid.org/0000-0001-5861-3342
  It should read:
  Carla Gentile MATAS https://orcid.org/0000-0002-9408-7172

Publication Dates

• Publication in this collection
  31 Jan 2020
• Date of issue
  Feb 2020

History

• Reviewed
  04 July 2019
• Received
  23 Aug 2019
• Accepted
  02 Sept 2019